A new report examined optic nerve lesion length, measured on brain magnetic resonance imaging, at the acute phase of ON in 51 individuals. Optic nerve lesion length was significantly associated with ...
Please provide your email address to receive an email when new articles are posted on . Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated ...
Retrospective data on patients with optic neuritis was recently used to study the prevalence and quality of asymptomatic optic nerve enhancement. The study found that roughly 1 in 6 (17%) inter-attack ...
Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...
NMOSD accounts for 1 to 2% of all cases of CNS inflammatory demyelinating disease in the United States and Europe, with multiple sclerosis being much more common, but NMOSD accounts for one third or ...
Stoke Therapeutics (NASDAQ:STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). FALCON is a ...
Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA––Changes in visual ...
About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic ...
Add Yahoo as a preferred source to see more of our stories on Google. Researchers say they have uncovered a link between semaglutide -- the active ingredient in Ozempic and Wegovy -- and the eye ...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...
Researchers say they have uncovered a link between semaglutide — the active ingredient in Ozempic and Wegovy — and sudden vision loss. The risk of developing non-arteritic anterior ischemic optic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results